Cipla will hold a meeting of the Board of Directors of the Company on 6 November 2019.

Powered by Capital Market - Live News

Shares of Cipla lost 3.64% to Rs 423.45. On the BSE, 28,000 shares were traded in the counter so far compared with average daily volumes of 84,000 shares in the past two weeks. The stock has hit an intraday low of Rs 423.35, which is also a 52-week low for the scrip. The scrip hit a high of Rs 432 so far during the day. It's 52-week high of Rs 663.45 was scaled on 3 October 2018.

Cipla announced on Saturday, 28 September 2019 that the inspection ended with 12 observations, none of which are related to data integrity. The company will respond to the agency within the stipulated timeline.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its markets like India, South Africa, North America, and key regulated and emerging markets. The company's strengths lie in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system agents (CNS) segments.

Powered by Capital Market - Live News

Cipla announced that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at its Goa manufacturing facility from 16-27 September 2019.

The inspection ended with 12 observations, none of which are related to data integrity. The Company will respond to the agency within the stipulated timeline.

Powered by Capital Market - Live News

Meanwhile, the S&P BSE Sensex was up 214.95 points or 0.56% to 38,808.47.

Shares of Cipla rose 1.28% to Rs 440 on the BSE. On the BSE, 8296 shares were traded in the counter so far compared with average daily volumes of 70,000 shares in the past two weeks. The stock hit a high of Rs 440 and a low of Rs 436.15 so far during the day.

The stock hit a 52-week high of Rs 677.45 on 27 September 2018. The stock hit a 52-week low of Rs 432 on 25 September 2019.

Cipla and its subsidiary Cipla USA, Inc., (hereafter referred to as Cipla) announced the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin® for Injection in the United States. The announcement was made after market hours yesterday, 25 September 2019.

According to IQVIA (IMS Health), Cubicin for Injection (daptomycin for injection) had U.S. sales of approximately $606 million for the 12-month period ended June 2019. The product is available for shipping immediately.

Cipla USA, Inc., is a wholly-owned subsidiary of Cipla Limited representing its direct market presence in the U.S. and focused on marketing pharmaceutical products in the retail and institutional spaces in the country.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its markets like India, South Africa, North America, and key regulated and emerging markets. The company's strengths lie in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system agents (CNS) segments.

Powered by Capital Market - Live News